Ensysce Biosciences board member Curtis Rosebraugh resigns effective April 1

Ensysce Biosciences disclosed that board member Curtis Rosebraugh resigned effective April 1, 2026, from both the Board of Directors and the Nominating and Corporate Governance Committee. The company provided no explanation for the departure, which is notable given that directors typically resign for specific reasons such as time commitments, disagreements with management, or concerns about company strategy.

For retail investors, unexplained board departures warrant attention because they can indicate underlying issues not yet public. Rosebraugh's role on the governance committee means the company has lost oversight in key areas like board composition and corporate policies. While a single resignation may be routine, the lack of explanation and timing should prompt investors to watch for any follow-on disclosures.

Investors should monitor whether the company appoints a replacement quickly and whether any additional departures or material disclosures follow in coming weeks. The next quarterly filing should provide more context on board composition and any governance changes.